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Abstract
Importance—Tourette syndrome (TS) is characterized by high rates of psychiatric comorbidity; 
however, few studies have fully characterized these comorbidities. Furthermore, most studies have 
included relatively few participants (<200), and none has examined the ages of highest risk for 
each TS-associated comorbidity or their etiologic relationship to TS.
Objective—To characterize the lifetime prevalence, clinical associations, ages of highest risk, 
and etiology of psychiatric comorbidity among individuals with TS.
Design, Setting, and Participants—Cross-sectional structured diagnostic interviews 
conducted between April 1, 1992, and December 31, 2008, of participants with TS (n = 1374) and 
TS-unaffected family members (n = 1142).
Main Outcomes and Measures—Lifetime prevalence of comorbid DSM-IV-TR disorders, 
their heritabilities, ages of maximal risk, and associations with symptom severity, age at onset, and 
parental psychiatric history.
Results—The lifetime prevalence of any psychiatric comorbidity among individuals with TS was 
85.7%; 57.7% of the population had 2 or more psychiatric disorders. The mean (SD) number of 
lifetime comorbid diagnoses was 2.1 (1.6); the mean number was 0.9 (1.3) when obsessive-
compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) were excluded, 
and 72.1% of the individuals met the criteria for OCD or ADHD. Other disorders, including mood, 
anxiety, and disruptive behavior, each occurred in approximately 30% of the participants. The age 
of greatest risk for the onset of most comorbid psychiatric disorders was between 4 and 10 years, 
with the exception of eating and substance use disorders, which began in adolescence 
(interquartile range, 15–19 years for both). Tourette syndrome was associated with increased risk 
of anxiety (odds ratio [OR], 1.4; 95% CI, 1.0–1.9; P = .04) and decreased risk of substance use 
disorders (OR, 0.6; 95% CI, 0.3–0.9; P = .02) independent from comorbid OCD and ADHD; 
however, high rates of mood disorders among participants with TS (29.8%) may be accounted for 
by comorbid OCD (OR, 3.7; 95% CI, 2.9–4.8; P < .001). Parental history of ADHD was 
associated with a higher burden of non-OCD, non-ADHD comorbid psychiatric disorders (OR, 
1.86; 95% CI, 1.32–2.61; P < .001). Genetic correlations between TS and mood (RhoG, 0.47), 
anxiety (RhoG, 0.35), and disruptive behavior disorders (RhoG, 0.48), may be accounted for by 
ADHD and, for mood disorders, by OCD.
Conclusions and Relevance—This study is, to our knowledge, the most comprehensive of its 
kind. It confirms the belief that psychiatric comorbidities are common among individuals with TS, 
demonstrates that most comorbidities begin early in life, and indicates that certain comorbidities 
may be mediated by the presence of comorbid OCD or ADHD. In addition, genetic analyses 
suggest that some comorbidities may be more biologically related to OCD and/or ADHD rather 
than to TS.
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Introduction
Tourette syndrome (TS) is a childhood-onset neuropsychiatric disorder characterized by 
multiple motor tics and 1 or more vocal tics that persist for at least 1 year.1,2 Multiple 
comorbid psychiatric disorders have been reported in TS-affected individuals; when present, 
these conditions typically cause more distress and impairment than do tics.3– 7 High rates of 
comorbid attention-deficit/hyperactivity disorder (ADHD) and obsessive-compulsive 
disorder (OCD) have been well documented and are thought to be core components of the 
TS phenotype.4,8– 11 Although elevated rates for mood disorders, nonobsessional anxiety 
disorders, and disruptive behavior disorders (DBDs) have also been reported,4,12– 17 a 
significant gap in knowledge still exists regarding the range, prevalence, and clinical 
attributes of the non-OCD, non-ADHD comorbid disorders. The few available studies were 
limited by small sample sizes (<200 participants),3,7,18–20 small number of diagnoses 
examined, or reliance on symptom checklists and severity scales rather than DSM-based, 
structured diagnostic psychiatric assessments.18,21– 24
Despite methodologic limitations, these studies12,13,15 suggest that a high proportion of 
individuals with TS (61%–96%) have at least 1 comorbid psychiatric disorder. 
Unfortunately, there is no consensus regarding expected rates of the noncore (ie, non-OCD, 
non-ADHD) psychiatric disorders in TS-affected individuals; in addition, there is limited 
knowledge regarding typical age at onset, ages of highest risk, and association with 
impairment for these disorders.
Although the shared genetic susceptibility to OCD and ADHD in TS-affected families has 
been established,25– 27 the etiologic relationships between TS and other psychiatric disorders 
have not been examined. Elevated rates of psychiatric comorbidity may arise from (1) 
shared genetic susceptibility with TS, (2) shared genetic susceptibility with comorbid OCD 
or ADHD, or (3) nongenetic factors (eg, shared environment). Together with quantifying the 
extent of concomitant occurrence, understanding the clinical and etiologic relationships 
between TS, OCD, ADHD, and other psychiatric comorbidities will help in understanding 
the sources of heterogeneity of this complex neuropsychiatric disorder. Therefore, the aims 
of the present study were to quantify psychiatric disorder burden, ages of highest risk, and 
underlying genetic relationship of psychiatric disorders in TS-affected individuals using the 
largest, most comprehensive data set available.
Methods
The study was described to all participants; adults provided written informed consent and 
children written assent before participating. Parents provided written consent for their 
children’s participation. Institutional review board approval was obtained from all 
participating sites. The participants did not receive financial compensation. The eAppendix 
in the Supplement includes the inclusion and exclusion criteria and informed consent details.
Participants
Phenotypic data were collected for genetic studies from TS-affected individuals aged 6 years 
or older and their parents and siblings, ascertained from 802 independent families between 
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April 1, 1992, and December 31, 2008. Recruitment primarily occurred from tic disorder 
specialty clinics in the United States, Canada, Great Britain, and the Netherlands as well as 
from the Tourette Syndrome Association of the United States.
Phenotypic Assessments
A psychiatrist, neurologist, or psychologist trained in the use of clinical research 
assessments evaluated all participants (D.L.P., Y.D., M.A.G., C.I., R.A.K., P.S., W.M.M., 
D.C.C., R.K., M.M.R., and C.A.M.).28 Tics, OCD, and ADHD symptoms were assessed 
using a structured clinical interview specifically developed for TS genetic studies 
(eAppendix in the Supplement). The Structured Clinical Interview for DSM-IV Axis I 
Disorders–Non-Patient Edition, 2.029 (all sites except the University of Utah site) or the 
Schedule for Affective Disorders and Schizophrenia–Lifetime Version, Modified for the 
Study of Anxiety Disorders30 (University of Utah site) was used to gather data on DSM-IV-
TR diagnoses for adults. The Schedule for Affective Disorders and Schizophrenia for 
School-Age Children, the Lifetime Version31 (all sites except Johns Hopkins University 
School of Medicine or University of Toronto) or the Epidemiologic Version32 (Johns 
Hopkins University School of Medicine and University of Toronto sites) was used to collect 
data on DSM-IV-TR diagnoses in children and adolescents. Final diagnoses were assigned 
using a best-estimate process, which requires diagnostic consensus by at least 2 raters.28,33 
We grouped individual disorders into DSM-IV-TR–based categories (eg, anxiety disorders) 
to aid in clinical interpretation. The eAppendix in the Supplement includes details regarding 
diagnostic instruments, rater training and reliability, age-at-onset determination, and the 
best-estimate process.
Statistical Analysis
For lifetime prevalence estimates of comorbid disorders and ages at onset, we limited the 
sample to the 1374 participants with TS. We also examined the lifetime prevalence of 
disorders among probands compared with their TS-affected first-degree relatives 
(eAppendix in the Supplement). To examine the association among TS, OCD, and ADHD 
with other comorbid disorders and for heritability analyses, we included all individuals, 
including TS-unaffected family members. We compared the rates of comorbid disorders by 
sex and age at interview using χ2 and Fisher exact tests. We examined the relationship 
between psychiatric comorbidity and TS, OCD, and ADHD by comparing lifetime 
prevalence rates of comorbid disorders among participants with TS only, TS and OCD only 
(TS+OCD), TS and ADHD only (TS+ADHD), and TS with both OCD and ADHD (TS
+OCD+ADHD) using χ2 tests. We used generalized estimating equations to examine the 
association of TS, ADHD, and OCD (individually and in combination) with other comorbid 
disorders, controlling for family relationships, age at interview, and sex.
For each disorder, we graphed the number of individuals with each age at onset using violin 
plots along with the median value and corresponding interquartile range. Age of highest risk 
was defined as the age at which the cumulative risk exceeded 10% (lower bound) through 
the upper bound of the interquartile range.
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Using generalized estimating equation models clustering on family and controlling for age at 
interview and sex, we tested the association between the presence of 1 or more comorbid 
disorder (excluding OCD and ADHD) with OCD and tic severity; OCD and ADHD; 
parental history of OCD, ADHD, and TS; and TS, OCD, and ADHD ages at onset. To 
improve clinical interpretation, we transformed continuous severity measures into 3 
categories (low, medium, and high) and ages at onset into early and late onset so that there 
were approximately equal numbers of participants in each group. Variables from each 
generalized estimating equation model with a significance level of P ≤ .20 were added 
simultaneously to a multivariate model.
We calculated the additive genetic and environmental correlations between TS and classes 
of comorbid disorders using the Sequential Oligogenic Linkage Analysis Routines (SOLAR, 
version 6.2.2)34 (eAppendix and eFigure in the Supplement). For these analyses, TS was 
combined with chronic motor or vocal tic disorders (CMVTDs). We did not examine the 
heritability of psychotic or eating disorders because of the low prevalence rates or of 
elimination disorders because of missing parental data.
Results
Demographic Characteristics
The sample consisted of 1374 TS-affected individuals, including parents or siblings without 
a TS diagnosis who met the best estimate criteria for TS (583 [42.4%]), and 1142 TS-
unaffected first-degree relatives. The subsample of TS-affected individuals showed a 3:1 
male predominance (1006 [73.2%] male), and the mean (SD) age at assessment was 19.1 
(13.5) years. Demographics and clinical characteristics of TS-affected and TS-unaffected 
participants are presented in eTable 1 in the Supplement.
Overall Burden of Psychiatric Comorbidity
Of the participants with TS, 85.7% met the criteria for 1 or more comorbid disorder 
(including OCD and ADHD) and 57.7% met the criteria for 2 or more comorbid disorders. 
Lifetime prevalence rates for classes of comorbid disorders are summarized in Table 1; rates 
of individual disorders by sex and age are presented in eTable 2 and eTable 3, respectively, 
in the Supplement. The mean (SD) number of lifetime disorders was 2.1 (1.6). When OCD 
and ADHD were excluded, 45.3% of the patients met the criteria for 1 or more comorbid 
disorder and 23.6% met the criteria for 2 or more comorbid disorders. The mean number of 
lifetime diagnoses, excluding OCD and ADHD, was 0.9 (1.3). There were no significant 
differences in the rates of comorbid diagnoses between probands and TS-affected relatives 
when controlling for age at assessment (eTable 4 in the Supplement); therefore, subsequent 
analyses combined these groups.
Prevalence of Specific Psychiatric Disorders
OCD and ADHD—The most common comorbid psychiatric disorders were OCD (50.0%) 
and ADHD (54.3%); 72.1% of the TS-affected participants met the criteria for either 
disorder. Females were more likely to have comorbid OCD (57.1% vs 47.5%; P < .01), and 
males were more likely to have comorbid ADHD (58.5% vs 42.3%; P < .01). Nearly one-
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third (29.5%) of the participants had TS+OCD+ADHD, 20.2% had TS+OCD, 22.4% had TS
+ADHD, and 27.9% had TS only. There was a significant interaction of sex and age with 
diagnostic group (χ2 = 43.1, P < .001; and χ2 = 121.6, P < .001, respectively).
Other Conditions—After OCD and ADHD, mood disorders, anxiety disorders, and 
DBDs were the most prevalent classes of psychiatric comorbidity, each affecting 
approximately 30% of TS-affected participants; psychotic disorders were the least common 
(<1%). The prevalence of individual disorders ranged from 0.5% (bipolar II disorder) to 
26.1% (major depressive disorder) (eTables 2–5 in the Supplement). Females were more 
likely to have major depressive disorder, most anxiety disorders, and eating disorders. Males 
were more likely to have ADHD and DBD (oppositional defiant disorder or conduct 
disorder) (Table 1 and eTable 2 in the Supplement). Adults and adolescents were most likely 
to have OCD as well as mood, anxiety, eating, and substance use disorders, whereas 
children were more likely to have ADHD (eTable 3 in the Supplement).
There was a clear relationship between OCD, ADHD, and the other psychiatric 
comorbidities in TS-affected participants. Mood, anxiety, and substance use disorders were 
more prevalent among participants with TS+OCD and TS+OCD+ADHD than among those 
with TS-only or TS+ADHD. Disruptive behavior disorders and psychotic disorders were 
more prevalent among participants with TS+OCD+ADHD than among the other 3 groups 
(Figure 1 and eTable 5 in the Supplement). When these analyses were repeated for males 
and females separately using the diagnostic groups shown in Figure 1, patterns of 
significance for χ2 analyses were comparable to those for all TS-affected participants 
combined, except for psychotic disorders, which is attributable to small sample sizes (eTable 
5 in the Supplement).
To assess the relationships between TS, OCD, ADHD, and psychiatric comorbidity, we 
conducted a multivariate generalized estimating equation model in all individuals (eTable 6 
in the Supplement). After controlling for OCD and ADHD, TS was independently 
associated with an increased risk of anxiety disorders (odds ratio [OR], 1.4; 95% CI, 1.0–
1.9; P = .04) and a decreased risk of substance use disorder (OR, 0.6; 95% CI, 0.3–0.9; P = .
02); there was no significant independent association between TS and mood disorder or 
DBD. Obsessive-compulsive disorder was independently associated with a 2-fold or greater 
risk of mood disorders (OR, 3.8; 95% CI, 2.9–4.9; P < .001), anxiety disorders (OR, 2.8; 
95% CI, 2.2–3.6; P < .001), DBDs (OR, 2.0; 95% CI, 1.4–2.9; P < .001), and substance use 
disorders (OR, 3.9; 95% CI, 2.5–6.0; P < .001). Attention-deficit/hyperactivity disorder was 
independently associated with an increased risk of anxiety disorders (OR, 1.5; 95% CI, 1.2–
2.0; P < .01) and DBDs (OR, 4.0; 95% CI, 2.6–6.2; P < .001) but not substance use or mood 
disorders. There were no significant associations between TS, OCD, ADHD, and 
elimination or eating disorders. The results of these models build on those summarized in 
Figure 1 because they control for the age and sex of the participants.
Age of Highest Risk—The median age at onset for TS was 6 years (interquartile range, 
4–8 years) (Figure 2 and eTable 7 in the Supplement). Attention-deficit/hyperactivity 
disorder and DBD had the youngest median age at onset and earliest ages of highest risk (5 
years: interquartile ranges, 3–6 and 3–8, respectively). The high-risk period began at age 4 
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years for anxiety disorders, 7 years for mood disorders, and 13 years for substance use and 
eating disorders. Compared with males, females tended to have later ages at onset of TS, 
DBDs, anxiety disorders, and mood disorders (eTable 7 in the Supplement).
Clinical Correlates of Number of Psychiatric Disorders
High tic and moderate/high OCD symptom severity, lifetime prevalence of ADHD or OCD, 
and parental history of TS/CMVTD and ADHD were associated with having 1 or more 
noncore psychiatric comorbidity in univariate analyses (Table 2). In the multivariate model, 
only high tic severity (OR, 1.57; 95% CI, 1.11–2.21; P = .01), ADHD (OR, 1.51; 95% CI, 
1.12–2.03; P < .01), OCD (OR, 1.77; 95% CI, 1.34–2.35; P < .001), and parental history of 
ADHD (OR, 1.55; 95% CI, 1.08–2.23; P = .02) remained significant. Obsessive-compulsive 
disorder severity was omitted from the multivariate model to avoid confounding with OCD 
diagnosis.
Genetic Relationships With TS
Consistent with previous findings,26,35 including those from a subset of the current sample, 
TS/CMVTD, OCD, and ADHD all demonstrated significant genetic correlations (eTable 8 
in the Supplement). In addition, TS/CMVTD had significant genetic correlations with mood 
disorders (RhoG [SE], 0.47 [0.17]; P = .004), anxiety disorders (RhoG [SE], 0.35 [0.15]; P 
= .02), and DBDs (RhoG [SE], 0.40 [0.18]; P = .02); these correlations were not significant 
when controlling for OCD and ADHD (eTable 9 in the Supplement). Mood disorders, 
anxiety disorders, and DBDs were also genetically correlated with ADHD; these 
correlations remained significant after controlling for TS/CMVTD and OCD (Table 3). 
Furthermore, mood disorders were significantly genetically correlated with OCD, even 
when controlling for TS/CMVTD and ADHD (Table 3).
Discussion
This study represents the most comprehensive examination to date of the extent and burden 
of comorbid psychiatric disorders in TS, and is the first to report ages of highest risk and 
etiological relationships with TS for a wide variety of psychiatric conditions. Our results 
have implications both clinically and for ongoing research into the causes and etiological 
relationships between these psychiatric disorders.
Clinical relevance
Consistent with previous studies3,4,12,15,36–39, we identified a very high burden of 
psychiatric disorders. Our results suggest that the vast majority of children with TS can be 
expected to develop ≥1 comorbid psychiatric disorder over their lifetime, and more than half 
will develop two. In addition to high rates of OCD (50.0%) and ADHD (54.3%), we also 
found high rates of mood (29.8%), anxiety (36.1%), DBD (29.7%), and elimination 
disorders (16.2%). We found relatively low rates of psychotic disorders and substance abuse 
at the time of evaluation, although we do not have longitudinal data later on in life for the 
younger individuals, when such disorders typically manifest.
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Importantly, this study is the first to report ages of highest risk for comorbid psychiatric 
disorders, as well as the relationship of demographic and clinical characteristics with overall 
disorder burden in TS. For most disorders, the age of greatest risk began before age 5, with 
high risk for anxiety and DBD continuing into adolescence, and risk for depressive disorders 
continuing into young adulthood. Previous research has demonstrated that TS symptoms 
typically emerge between the ages of 5 and 7 years13,40, while ADHD generally appears 2 to 
3 years earlier41, and OCD 5 to 6 years later42. In this study, DBD and ADHD began at or 
before age 5, prior to tic onset. In contrast to population-based epidemiologic studies43,44, 
OCD and anxiety disorders also began early, typically within a year of onset of tics (with 
many cases beginning earlier); mood disorders had a more distributed age-of-onset pattern, 
beginning as early as age 5, and becoming more frequent around ages 7–8. These results, in 
combination with the high likelihood of developing a mood, anxiety, or DBD, suggest that 
psychiatric assessments of TS-affected children should begin early and continue throughout 
adolescence and adulthood.
Our results also suggest that TS-affected children who also have OCD or a parent with 
ADHD in particular should be carefully evaluated over time for the development of mood, 
anxiety, and DBD, and adolescents, particularly those with OCD and/or ADHD, should also 
be monitored for the development of a substance use disorder. Similarly, TS-affected 
children with ADHD should be evaluated for other DBD and anxiety disorders. The 
association between high tic severity and the number of non-ADHD/non-OCD 
comorbidities is consistent with a previous study demonstrating an association between tic 
severity and non-OCD anxiety disorders12.
Etiological relevance
The heritability estimates confirm previous research26,35 showing that TS, OCD, and ADHD 
are highly genetically related. However, for the first time, we also provide evidence of a 
strong genetic relationship between these TS-related phenotypes and mood, anxiety, and 
DBD. Of particular interest, our analyses suggest that the observed genetic correlations 
between TS and these disorders are better accounted for by an underlying genetic 
relationship with ADHD and, in the case of mood disorders, by an underlying genetic 
relationship with both ADHD and OCD. In non-TS samples, there is considerable 
evidence45 to support shared genetic variance between ADHD and DBD, and some data46 to 
support a shared genetic diathesis underlying ADHD and major depressive disorder. Genetic 
relationships between OCD and mood disorders have not previously been examined. Our 
findings are in line with a previous study that found no increased rates of ADHD47 or other 
non-OCD disorders such as anxiety, affective, substance abuse and psychotic disorders,48 
among parents of probands with TS compared to controls, suggesting that these disorders 
segregate independently from TS. Our findings that parental history of ADHD predicts 
psychiatric disorder burden in TS-affected offspring, independent of parental history of TS 
and OCD, provides additional support for the observed genetic relationships between 
psychiatric disorders and ADHD.
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Limitations
This study has several limitations. First, our data are cross-sectional, thus, we cannot assess 
causation (e.g., whether clinical characteristics predicted subsequent disorder onset). 
Second, the predominately clinic-based recruitment may have biased our sample to 
participants with more severe, comorbid, or familial TS, limiting generalizability. This 
concern is somewhat mitigated by the presence of parents and previously undiagnosed 
siblings with TS, who were typically less severely affected. Third, although consistent with 
previous studies, the total psychiatric burden identified is likely an underestimate, given that 
some disorders were not assessed (e.g., pervasive developmental disorders [PDDs]) and not 
everyone had passed the age of risk for all disorders. Specifically, parents were not routinely 
assessed for certain childhood disorders (e.g., elimination disorders) and children were not 
assessed for schizophrenia, although they were assessed for psychosis. Similarly, the 
lifetime rates of schizophrenia, bipolar disorder, and substance use disorders could be 
attenuated by an ascertainment bias (i.e., the children and adolescents in our sample may 
have developed these adult-onset disorders later in life). Fourth, ADHD severity was not 
uniformly assessed. Fifth, we did not have reliable data regarding recruitment method (i.e., 
TSA vs. specialty clinics), and characteristics of participants may vary by recruitment 
method. Sixth, PDDs were not systematically assessed or uniformly excluded; future studies 
should examine patterns of comorbidity between TS and PDDs49. Finally, because the 
parent genetic study focused on sibling pairs and parent-child trios, the heritabilities may be 
underestimates, as the algorithm employed by SOLAR is best suited to analysis of 
multigenerational families.
Conclusions
This study provides important new data regarding the prevalence, predictors, and ages of 
highest risk for psychiatric illness among individuals affected with TS, as well as for the 
first time formally evaluating the etiological relationships between disorders other than OCD 
and ADHD. The key clinical findings, that mood, anxiety, and DBD are very common 
among TS-affected individuals, tend to begin early in life, and are highly associated with 
comorbid OCD and ADHD, are of direct and immediate relevance for practitioners. The 
genetic analyses advance our understanding of the etiological relationships between TS and 
other psychiatric disorders, and provide a framework for future studies aimed at better 
understanding the biology of these complex, inter-related syndromes.
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Figure 1. 
Lifetime Prevalence of Comorbid Disorders by Presence of OCD and ADHD Among 
Individuals with Tourette Syndrome. Significance values reflect individual 4-by-2 χ2 tests 
(i.e., TS/OCD/ADHD group by presence of the comorbid disorder).
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Figure 2. 
Ages-of-Onset for Comorbid Disorders Among Individuals with Tourette Syndrome. Points 
and bars represent median ages-of-onset and interquartile ranges, respectively. Width of 
each plot is proportional to the number of individuals with the given age of onset.
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Table 1
Lifetime Prevalence of Psychiatric Disorders by Sex
Comorbid disorder Sex
All TS-affected
participants
n/total with available
data (%)
Male
n/total with available
data (%)
Female
n/total with available
data (%)
p-value
Obsessive compulsive spectrum disorders a 904/1368 (66.1) 645/1001 (64.4) 259/367 (70.6) .03
Attention-deficit/hyperactivity disorder 713/1314 (54.3) 564/962 (58.6) 149/352 (42.3) < .001
Mood disorders b 277/930 (29.8) 184/690 (26.7) 93/240 (38.8) < .001
Anxiety disorders c 343/949 (36.1) 225/703 (32.0) 118/246 (48.0) < .001
Disruptive behavior disorders d 185/622 (29.7) 157/493 (31.9) 28/129 (21.7) .03
Eating disorders e 19/937 (2.0) 2/693 (0.3) 17/244 (7.0) < .001
Psychotic disorders f 7/931 (0.8) 5/689 (0.7) 2/242 (0.8) .88
Substance use disorders g 59/948 (6.2) 42/701 (6.0) 17/247 (6.9) .62
Elimination disorders h 108/668 (16.2) 90/531 (17.0) 18/137 (13.1) .28
Chi-squared or Fisher’s exact test were used to compare rates of each disorder in males vs females.
a
Includes: obsessive-compulsive disorder and subclinical obsessive-compulsive disorder,
b
major-depressive disorder, dysthymia, and bipolar disorder I and II,
cgeneralized anxiety disorder, panic disorder, agoraphobia without panic, posttraumatic stress disorder, separation anxiety disorder, social phobia, 
and specific phobia,
d
oppositional-defiant and conduct disorders,
e
anorexia and bulimia nervosa,
f
schizophrenia and psychotic disorder, not otherwise specified,
g
alcohol and other substance use or dependence, excluding tobacco use, and
h
enuresis and encopresis.
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Table 2
Clinical Predictors of Having ≥ 1 Comorbid Disorder, Excluding OCD and ADHD
Characteristic (reference value) Levels OR (95% CI) p-values
Symptom severity a
  Tic severity tertiles (0–16)
17–21 1.18 (0.90—1.55) .24
22–30 1.87 (1.43—2.46) <.001
  OCD severity tertiles (0–2)
3–6 1.64 (1.26—2.13) <.001
7–12 2.86 (2.13—3.82) <.001
Comorbid conditions
  ADHD (no ADHD) ADHD present 1.93 (1.53—2.43) <.001
  OCD (no OCD) OCD present 2.17 (1.75—2.70) <.001
Parental history b
  Parental history of TS/CMVTD (parental TS/CMVTD absent) Parental TS/CMVTD present 1.33 (1.01—1.76) .04
  Parental history of OCD (parental OCD absent) Parental OCD present 1.11 (0.84—1.47) .46
  Parental history of ADHD (parental ADHD absent) Parental ADHD present 1.86 (1.32—2.61) <.001
Age of onset
  TS age of onset (≥7 y) < 7 y 1.02 (0.82—1.29) .84
  OCD age of onset (≥8 y) < 8 y 1.10 (0.74—1.64) .63
  ADHD age of onset (≥ 5 y) < 5 y 1.35 (0.90—2.01) .14
Separate generalized estimating equations, clustering on family and controlling for age at interview and sex, were modeled with the presence of ≥ 1 
comorbid disorder, other than ADHD or OCD, as the outcome and each clinical characteristic as the predictor variable.
aSymptom severity scales for tics and obsessive-compulsive symptoms are described in the Supplemental Methods.
b
Parental history only available for probands and their full siblings.
ADHD, attention-deficit/hyperactivity disorder; CMVTD, chronic motor or vocal tic disorder; OCD, obsessive-compulsive disorder; TS, Tourette 
syndrome
JAMA Psychiatry. Author manuscript; available in PMC 2015 May 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Hirschtritt et al. Page 17
Ta
bl
e 
3
B
iv
ar
ia
te
 H
er
ita
bi
lit
y 
of
 C
om
or
bi
d 
D
ia
gn
os
es
 w
ith
 T
S/
CM
V
TD
, O
CD
, a
nd
 A
D
H
D
N
o 
ad
di
tio
na
l d
ia
gn
os
tic
 co
va
ri
at
es
 a
C
ov
ar
yi
ng
 fo
r T
S 
a
C
ov
ar
yi
ng
 fo
r O
C
D
 o
r 
A
D
H
D
 a
, 
b
C
ov
ar
yi
ng
 fo
r T
S 
an
d 
O
C
D
 o
r 
A
D
H
D
 a
, 
b
C
om
or
bi
d
di
so
rd
er
R
ho
G
(S
E)
R
ho
G
 p
-
v
a
lu
e
R
ho
E
(S
E)
R
ho
E 
p-
v
a
lu
e
R
ho
G
(S
E)
R
ho
G
 p
-
v
a
lu
e
R
ho
E
(S
E)
R
ho
E 
p-
v
a
lu
e
R
ho
G
(S
E)
R
ho
G
 p
-
v
a
lu
e
R
ho
E
(S
E)
R
ho
E
p-
v
a
lu
e
R
ho
G
(S
E)
R
ho
G
 p
-
v
a
lu
e
R
ho
E
(S
E)
R
ho
E 
p-
v
a
lu
e
Bi
va
ri
at
e
he
ri
ta
bi
lit
y
w
ith
 A
D
H
D
M
oo
d
.
77 (.1
4)
1.
6 
× 
10
−
8
−
.
32
(.1
4)
2.
6 
× 
10
−
2
.
74 (.1
5)
3.
9 
× 
10
−
7
.
31 (.1
5)
.
03
.
68 (.1
8)
8.
6 
× 
10
−
5
−
.
29
(.1
4)
.
04
.
70 (.1
8)
2.
3 
× 
10
−
5
−
.
36
(.1
5)
.
02
A
nx
ie
ty
.
59 (.1
2)
3.
2 
× 
10
−
6
.
54 (.1
3)
5.
0 
× 
10
−
5
.
40 (.1
5)
7.
7 
× 
10
−
3
.
43 (.1
4)
3.
2 
× 
10
−
3
D
isr
up
tiv
e
be
ha
vi
or
.
68 (.1
5)
1.
9 
× 
10
−
5
.
66 (.1
6)
6.
9 
× 
10
−
5
.
62 (.1
7)
5.
3 
× 
10
−
4
.
61 (.1
7)
6.
2 
× 
10
−
4
Bi
va
ri
at
e
he
ri
ta
bi
lit
y
w
ith
 O
C
D
M
oo
d
.
59 (.1
3)
3.
5 
× 
10
−
5
.
34 (.1
1)
3.
2 
× 
10
−
3
.
53 (.1
5)
1.
1 
× 
10
−
3
.
40 (.1
1)
7.
2 
× 
10
−
4
.
47 (.1
7)
.
01
.
43 (.1
0)
1.
3 
×
10
−
4
.
41 (.1
8)
.
04
.
48 (.1
1)
3.
8 
× 
10
−
5
A
nx
ie
ty
.
40 (.1
2)
2.
7 
× 
10
−
3
.
55 (.1
1)
4.
2 
× 
10
−
6
.
34 (.1
3)
.
02
.
55 (.1
1)
1.
2 
× 
10
−
5
.
60 (.1
0)
2.
4 
×
10
−
7
.
62 (.1
1)
3.
6 
× 
10
−
7
D
isr
up
tiv
e
be
ha
vi
or
G
en
et
ic
 a
nd
 e
nv
iro
nm
en
ta
l c
or
re
la
tio
n 
(R
ho
G 
an
d R
ho
E,
 re
sp
ec
tiv
ely
) b
etw
ee
n T
S/C
M
VT
D 
an
d g
rou
ps
 of
 co
mo
rbi
d d
iso
rde
rs 
we
re 
est
im
ate
d; 
wh
ere
 R
ho
G 
wa
s s
ign
ifi
ca
nt,
 A
DH
D 
an
d O
CD
 w
ere
 ad
de
d s
ep
ara
tel
y a
s c
ov
ari
ate
s t
o a
sse
ss 
the
 in
de
pe
nd
en
t a
sso
ci
at
io
n 
be
tw
ee
n 
TS
/
CM
V
TD
 a
nd
 th
e 
gi
ve
n 
co
m
or
bi
d 
di
so
rd
er
s. 
Su
bs
eq
ue
nt
ly
, a
 se
rie
s o
f b
iv
ar
ia
te
 a
na
ly
se
s w
ith
 A
D
H
D
 a
nd
 O
CD
 w
er
e 
co
nd
uc
te
d 
fo
r d
iso
rd
er
s w
ith
 a
 si
gn
ifi
ca
nt
 R
ho
G
 w
ith
 T
S 
to
 d
et
er
m
in
e 
th
e 
un
iq
ue
 c
on
tri
bu
tio
ns
 o
f A
D
H
D
 a
nd
 O
CD
 to
 th
e 
ge
ne
tic
 c
or
re
la
tio
n 
be
tw
ee
n 
TS
 a
nd
 
ea
ch
 o
f t
he
se
 d
iso
rd
er
s (
mo
od
, a
nx
iet
y, 
an
d d
isr
up
tiv
e b
eh
av
ior
 di
so
rde
rs)
. B
lan
k c
ell
s r
ep
res
en
t n
on
-si
gn
ifi
ca
nt 
co
rre
lat
ion
s (
i.e
., p
>0
.5)
.
a
A
ll 
an
al
ys
es
 in
cl
ud
e 
se
x,
 a
ge
, a
nd
 se
x-
by
-a
ge
 a
s c
ov
ar
ia
te
s.
b I
n 
bi
va
ria
te
 a
na
ly
se
s w
ith
 A
D
H
D
, O
CD
 (n
ot 
AD
HD
) w
as 
inc
lud
ed
 as
 a 
co
va
ria
te;
 co
nv
ers
ely
, in
 bi
va
ria
te 
an
aly
ses
 w
ith
 O
CD
, A
DH
D 
(no
t O
CD
) w
as 
inc
lud
ed
 as
 a 
co
va
ria
te.
A
D
H
D
, a
tte
nt
io
n-
de
fic
it/
hy
pe
ra
ct
iv
ity
 d
iso
rd
er
; O
CD
, o
bs
es
siv
e-
co
m
pu
lsi
ve
 d
iso
rd
er
; T
S/
CM
V
TD
, T
ou
re
tte
 sy
nd
ro
m
e/
ch
ro
ni
c 
m
ot
or
 a
nd
 v
oc
al
 ti
c 
di
so
rd
er
JAMA Psychiatry. Author manuscript; available in PMC 2015 May 27.
